Goldman Sachs' downgrade of Cue Health from Buy to Neutral and the significant reduction in the price target from $2.75 to $0.75 indicates a less optimistic outlook for the stock. This could lead to a negative short-term impact on the stock price as investors may reevaluate their positions based on the new rating and price target.